FORE Biotherapeutics vs Remepy
FORE Biotherapeutics vs Remepy, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: FORE Biotherapeutics is on 56/100 and Remepy on 57/100.
Where each one leads
FORE Biotherapeutics
- domain rating: 33/100 against 21/100
- funding raised: $232M against $15.0M
Remepy
- headcount: 75 against 56
- headcount growth: +105.6% against +8.2%
- LinkedIn following: 6,458 against 4,584
At a glance
| Measure | FORE Biotherapeutics | Remepy |
|---|---|---|
| What it is | Precision oncology company developing cancer therapies guided by proprietary functional genomics. | Digital therapeutics platform enhancing drug efficacy and safety through personalized software. |
| Category | Healthcare, Drug Development, Genomics, Next Generation Sequencing | Healthcare, Drug Development, Biotech, Life Sciences |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Software |
| Founded | 2011 | 2021 |
| Headquarters | Philadelphia, United States | Tel Aviv, Israel |
| Status | Active | Active |
Size, funding and growth
| Measure | FORE Biotherapeutics | Remepy |
|---|---|---|
| Employees | 56 | 75 |
| Headcount growthLast 12 months | +8.2% | +105.6% |
| Total funding | $232M | $15.0M |
| Latest round | Series D-2 Extension | Seed |
| Valuation | $75.0M | Not published |
| LinkedIn followers | 4,584 | 6,458 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | FORE Biotherapeutics | Remepy |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 56/100 | 57/100 |
| Traction | 58/100 | 55/100 |
| Team | 70/100 | 70/100 |
| Search visibility | 38/100 | 38/100 |
| Quality | 55/100 | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (37/100) | D (40/100) |
| Domain ratingLink authority, 0-100 | 33/100 | 21/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | FORE Biotherapeutics | Remepy |
|---|---|---|
| CDN | Not detected | Cloudflare |
| CMS | WordPress | Webflow |
| Frameworks | Jquery | Not detected |
| Analytics | Not detected | Google Analytics 4, Google Tag Manager |
FORE Biotherapeutics vs Remepy: common questions
Which is better, FORE Biotherapeutics or Remepy?
On our 0-100 score Remepy rates higher (57/100 against 56/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do FORE Biotherapeutics and Remepy compare on the numbers?
FORE Biotherapeutics leads on domain rating (33/100 against 21/100), funding raised ($232M against $15.0M). Remepy leads on headcount (75 against 56), headcount growth (+105.6% against +8.2%), LinkedIn following (6,458 against 4,584).
Read the full FORE Biotherapeutics review and pricing or the Remepy review and pricing. You can also browse other FORE Biotherapeutics alternatives we track.